A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis

NCT06952465 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

2000

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Deucravacitinib
BIOLOGICAL: Any biologic treatment for psoriasis

Sponsor

Bristol-Myers Squibb